TScan Therapeutics Reports Q1 Results, Initiates Phase 3 for TSC-101, Extends Cash Runway
TCRX sits 36% above its 52-week low of $0.882.
Summary
TScan Therapeutics announced its first quarter 2026 financial results, highlighted by the planned initiation of a Phase 3 study for its lead candidate TSC-101 and a confirmed cash runway into the second half of 2027.
Key Events · Earnings and Guidance · TCRX
-
Phase 3 Study Initiation Planned
The company plans to initiate a pivotal Phase 3 study for its lead TCR-T therapy candidate, TSC-101, in the second quarter of 2026.
-
Cash Runway Extended
TScan Therapeutics reported cash and cash equivalents of $128.1 million as of March 31, 2026, which is expected to fund operations into the second half of 2027.
-
Pipeline Expansion with New Phase 1 Studies
The company plans to initiate Phase 1 studies for TSC-102-A01 and TSC-102-A03, targeting CD45, in the second half of 2026, which could approximately double the number of patients benefiting from TCR-T therapy.
-
Improved Q1 Financial Results
Net loss for the first quarter of 2026 improved to $28.7 million, compared to $34.1 million in the prior year, driven by reduced R&D and G&A expenses.
Analysis · TCRX · Life Sciences
This 8-K details TScan Therapeutics' first quarter 2026 financial performance and provides a comprehensive corporate update, which was simultaneously released via press release. For a clinical-stage biotechnology company, the planned initiation of a pivotal Phase 3 study for its lead candidate, TSC-101, in the second quarter of 2026 is a significant advancement, signaling progress towards potential commercialization. Furthermore, the confirmation of a cash runway into the second half of 2027 is crucial, providing financial stability and reducing near-term funding concerns. The company also outlined plans for new Phase 1 studies for TSC-102 candidates, expanding its heme malignancy franchise, and anticipates early data from its ALLOHA Phase 1 trial. While revenue decreased, the reduction in R&D and G&A expenses contributed to an improved net loss, demonstrating prudent financial management. These updates collectively present a positive outlook on the company's operational and clinical trajectory.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 37.1% of the 974 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TCRX was trading at $1.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $72.7M. The 52-week trading range was $0.88 to $2.57. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.